Back to search

Article

Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals

2022-06-13

Abstract excerpt

<h4>Background: </h4> Treatment of chronic hepatitis C (CHC) with direct acting antivirals (DAAS) improves the rates of sustained virological response (SVR). However, derangements with lipid profile and glycemic status have been observed. This study aimed to compare the effect of sofosbuvir/daclatasvir (SOF/DAC) versus sofosbuvir/ledipasvir (SOF/LED) regimens on metabolic status of CHC patients. <h4>Methods: </h4...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
32a59582-6abb-598a-b7d7-27474a6baa77
DOI
10.12688/f1000research.109397.1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metabolic changes in chronic hepatitis C patients receiving direct acting antiviralsDOI 10.12688/f1000research.109397.1
Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity
Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.Semantic proximity
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.Semantic proximity
Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Semantic proximity
Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.Semantic proximity
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].Semantic proximity
Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.Semantic proximity
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.Semantic proximity
Update on the treatment of hepatitis C genotypes 2-6.Semantic proximity
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.Semantic proximity
Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity
Select a neighboring publication to make it the new centre.